China’s NHSA Launches Work Plan for First National Medical Insurance Medical Service Catalogue – 13 Clinical Categories in Batch One Reshape Reimbursement Rules for Providers Nationwide

Beijing, China – 16 Sep 2026 – China’s National Healthcare Security Administration (NHSA) released the Work Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue, establishing a unified national catalogue of reimbursable medical service items — starting with 13 clinical categories including cardiovascular, respiratory, ophthalmology, gynecology, radiotherapy, anesthesia, nursing, clinical scale assessment, dental implants, assisted reproduction, obstetrics, radiological examination, and rehabilitation — to be applied first to cross‑province direct settlement and then progressively aligned with provincial payment scopes.

Policy Snapshot

ItemDetail
AuthorityNational Healthcare Security Administration (NHSA), China
DocumentWork Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue
Release Date16 September 2026
Legal BasisHealthcare Security Law of the PRC; CPC Central Committee & State Council Opinions on Deepening Healthcare Security System Reform; 1999 MOHRSS rules on diagnostic/treatment item management
First Batch Scope13 categories (incl. related items in other categories), to be expanded in batches alongside the national medical service price project listing guidelines
Initial ApplicationCross‑province direct settlement for out‑of‑town treatment; subsequently linked with provincial insurance payment scopes

Inclusion & Exclusion Criteria

  • Inclusion Baseline: Items must be listed in the current national medical service price project listing guidelines (trial), be clinically necessary, safe, effective and appropriately priced, and pose controllable impact on basic medical insurance fund expenditure without threatening fund security.
  • Explicit Exclusions: Items subject to market‑regulated pricing; non‑disease‑treatment services such as cosmetic procedures, weight loss, health checkups, prevention and wellness; services with insufficient clinical application, uncertain efficacy, or major safety risks; and anything else outside the basic insurance coverage scope.
  • Guiding Principle: The catalogue adheres to the “basic coverage” positioning of basic medical insurance — acting within capability, keeping total volume stable, and ensuring smooth transition, weighing fund affordability, clinical demand and social impact.

Work Program – Three Phases

  • Preparation Phase: Establish a dedicated task force and expert database; finalize work rules covering integrity, confidentiality and conflict‑of‑interest recusal; collect provincial data on price‑listing implementation, service pricing and payment status; and run fund modeling on the first batch’s insurance expenditure and the overall national cost envelope for medical services.
  • Review Phase: A survey across representative medical institutions at all levels in 31 provinces (regions, municipalities) plus the Xinjiang Production and Construction Corps; joint review by management and clinical experts scoring each item on inclusion merit, health benefit, clinical need, equity and cost‑effectiveness; expert discussion of restricted payment scopes; and a fund impact assessment with local insurance authorities before shortlisting items.
  • Publication Phase: The first‑batch catalogue is finalized based on expert opinions and fund impact modeling, submitted for approval per procedure, then issued to guide local implementation.

Governance & Expert Oversight

  • Expert Composition: Reviewers — insurance management, price management, health economics/HTA and clinical experts — are recommended by relevant departments or randomly drawn from the expert pool, with geographic balance, representation across institution types and tiers, and inclusion of primary‑care institution representatives.
  • Clinical Reviewer Scope: Clinical experts evaluate items only within their specialty fields.
  • Supervision Mechanisms: Disciplinary inspection and supervision bodies are invited to oversee preparation, review and publication; internal controls mandate role accountability, confidentiality, recusal and liability rules; experts sign non‑disclosure agreements, must commit to impartial service, are barred from unauthorized public activity in the catalogue‑expert capacity, and all proceedings are fully documented to preserve independence.

Market Impact & Outlook

  • Reimbursement Architecture: A unified national service catalogue replaces the current patchwork of provincial coverage lists — a structural shift for hospitals’ revenue predictability and for cross‑province settlement efficiency serving China’s large migrant population.
  • Provider Strategy: Medical institutions should map their service portfolios against the 13 first‑batch categories and the inclusion criteria, anticipating which items may face restricted payment scopes or exclusion as market‑priced services.
  • Sector Winners & Watchpoints: Categories inside the catalogue — notably dental implants, assisted reproduction, rehabilitation and radiotherapy — gain clearer reimbursement visibility, while cosmetic, wellness and weight‑loss services are explicitly ring‑fenced outside basic insurance.
  • Phased Expansion: Subsequent batches will follow the rollout of national price project listing guidelines, signaling a multi‑year build‑out toward full national standardization of insured medical services.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the formulation, approval and implementation of China’s national medical insurance medical service item catalogue. The work plan remains subject to consultation, expert review and fund impact assessment; the final catalogue composition, payment restrictions, effective dates and local implementation may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ylbz.gansu.gov.cn/ylbzj/c105248/202609/174394881.shtml

NMPA’s CMDE Opens Public Consultation on Revised Guidelines for Tuberculosis Drug‑Resistance Gene Mutation Detection Reagents – 2026 Revision Signals Tightened Review Standards for Molecular TB Diagnostics in China

Beijing, China – 16 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on the revised draft guideline, Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition) (Draft for Comments), aimed at standardizing technical review requirements and guiding registration applicants in preparing submission dossiers, with feedback due by 15 October 2026.

Consultation Snapshot

ItemDetail
AgencyCMDE, under the National Medical Products Administration (NMPA), China
ActionPublic solicitation of opinions on a revised draft registration review guideline
DocumentGuidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition, Draft for Comments)
PurposeStandardize technical review requirements; guide applicants in preparing and writing registration dossiers
Notice Date16 September 2026
Comment Deadline15 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Noticecmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

  • Product Scope: The guideline covers in vitro diagnostic reagents that detect resistance‑associated gene mutations in the Mycobacterium tuberculosis complex — molecular tests used to identify drug‑resistant TB (including multidrug‑resistant TB) directly from clinical specimens, in contrast to slower culture‑based drug susceptibility testing.
  • Revision, Not First Edition: CMDE has revised the existing guideline rather than issuing an inaugural document, indicating updates to review expectations accumulated from prior registration experience. The specific changes were not disclosed in the notice; the full draft is available for download from CMDE.
  • Submission Format: Comments must be filed via the official feedback form (Annex 2) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
  • Contacts: Cheng Xi, Liu Rongzhi (+86‑10‑86452580, +86‑10‑86452532; chengxi@cmde.org.cn, liurz@cmde.org.cn).

Sector Background

  • Molecular Resistance Detection: Gene mutation assays — typically PCR‑based — identify resistance‑conferring mutations (e.g., in rpoB for rifampicin resistance) within hours, enabling rapid treatment decisions versus weeks for phenotypic testing.
  • Public Health Priority: China remains among the countries with the highest TB and multidrug‑resistant TB burden globally, making fast, accurate resistance detection central to national TB control programs and the WHO End TB Strategy.
  • IVD Registration Environment: CMDE technical review guidelines define the evidentiary expectations (analytical performance, clinical studies, reference comparators) for IVD registration in China; public consultation is the standard step before finalization.

Market Impact & Outlook

  • Regulatory Predictability: A revised, codified standard reduces dossier ambiguity for IVD sponsors and shortens the review cycle for resistance‑detection assays targeting the M. tuberculosis complex.
  • Competitive Landscape: Domestic molecular diagnostics developers — alongside global IVD players active in China’s TB testing market — should benchmark their clinical evidence and performance claims against the 2026 draft before launching new registrations or renewals.
  • Portfolio Implications: Manufacturers with existing TB resistance‑detection products should assess whether current dossiers and performance data meet the revised expectations, particularly on mutation coverage and clinical concordance requirements.
  • Participation Window: Stakeholders have until 15 October 2026 to influence the final guideline — an opportunity to raise practical issues on reference standards, comparator selection, and multi‑center clinical study design.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guideline, and its potential impact on in vitro diagnostic registration in China. The draft is subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916144510144.html

NMPA’s CMDE Opens Public Consultation on Draft Review Guidelines for AI Multi‑Disease Decision Devices and Deep Brain Stimulation Systems – Standardized Review Pathways Signal Next Phase of China MedTech Regulation

Beijing, China – 15 Sep 2026 – The Center for Medical Device Evaluation (CMDE) of China’s National Medical Products Administration (NMPA) announced a public consultation on two draft registration review guidelines — the Guidelines for Clinical Evaluation and Registration Review of AI‑Assisted Multi‑Disease Decision‑Making Medical Devices (Draft for Comments) and the Guidelines for Clinical Evaluation and Registration Review of Implantable Deep Brain Stimulation (DBS) Systems (Draft for Comments) — with feedback due by 14 October 2026.

Consultation Snapshot

ItemDetail
AgencyCMDE, under the National Medical Products Administration (NMPA), China
ActionPublic solicitation of opinions on two draft technical review guidelines
Document 1AI‑assisted multi‑disease decision‑making medical devices – clinical evaluation & registration review
Document 2Implantable deep brain stimulation (DBS) systems – clinical evaluation & registration review
Notice Date15 September 2026
Comment Deadline14 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Noticecmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

  • Document 1 – AI Multi‑Disease Decision Devices: Targets software‑based devices that assist clinical decision‑making across multiple diseases, defining clinical evaluation and registration review requirements. Detailed technical provisions were not disclosed in the notice itself; the full draft is available for download from CMDE.
  • Document 2 – Implantable DBS Systems: Sets out clinical evaluation and registration review requirements for implantable deep brain stimulation systems, a class of active implantable neurostimulation devices.
  • Submission Format: Comments must be filed via the official feedback form (Annex 3) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
  • Contacts – AI Guideline: Wang Zehua, Jiang Yan, Dong Zheng (wangzh@cmde.org.cn, jiangyan@cmde.org.cn, dongzheng@cmde.org.cn).
  • Contacts – DBS Guideline: Cui Xinyue, Guo Jiaying, Jin Yaxi (cuixy@cmde.org.cn, guojy@ydcmdei.org.cn, jinyx@cmde.org.cn) — with a Shanghai contact number indicating involvement of CMDE’s Yangtze River Delta branch.

Sector Background

  • AI as a Medical Device (SaMD): China has progressively built a review framework for AI‑enabled diagnostic software. Extending dedicated guidance to multi‑disease decision support reflects the regulator’s response to algorithms that synthesize patient data across indications rather than addressing a single disease — a materially more complex clinical evaluation problem.
  • Deep Brain Stimulation: DBS is an established implantable therapy for movement disorders such as Parkinson’s disease, with China’s market served by both global manufacturers (Medtronic, Abbott, Boston Scientific) and domestic players (PINS Medical, SceneRay).
  • Guideline System: CMDE technical review guidelines standardize registration dossiers and evaluation criteria; public consultation is the customary step before guidelines are finalized and take effect.

Market Impact & Outlook

  • Regulatory Clarity: Codified evaluation criteria for AI decision‑support software and implantable neurostimulators reduce approval uncertainty for developers and shorten pre‑submission negotiations.
  • AI‑MedTech Landscape: Sponsors of multi‑disease AI platforms — including hospital‑affiliated developers and health‑AI startups — should benchmark their clinical evidence strategies against the draft before the final guideline lands.
  • Neuromodulation Standardization: A dedicated DBS guideline aligns China’s review expectations with the maturity of its neurostimulation market, benefiting both multinationals and domestic manufacturers pursuing registration or next‑generation product iterations.
  • Participation Window: Industry stakeholders have until 14 October 2026 to shape the final requirements — an opportunity to flag practical concerns on clinical evaluation design, real‑world evidence, and post‑market obligations.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of draft guidelines, and their potential impact on medical device registration in China. The drafts are subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916105408164.html